A new selective fluorescent probe based on tamoxifen by Ho, L. et al.
 1 
A new selective fluorescent probe based on tamoxifen  
Louisa A. Ho,[a] Elizabeth Thomas,[b] Robert A. McLaughlin,[c] Gavin R. Flematti,[a]  and Rebecca O. Fuller*[a] 
 
[a] School of Chemistry and Biochemistry M310, The University of Western Australia, 35 Stirling 
Hwy, Crawley WA 6009, Australia. 
[b] School of Surgery M507, The University of Western Australia, QEII Medical Center, Monash 
Ave, Nedlands, WA 6009, Australia. 
[c] Australian Research Council Center of Excellence for Nanoscale Biophotonics. School of 
Medicine, University of Adelaide, Adelaide, SA 5005 Australia 
 
Corresponding author:* Dr Rebecca Fuller 
         School of Chemistry and Biochemistry, M310 
         The University of Western Australia 
         35 Stirling Hwy 
         Crawley, WA 6009 Australia 
         Tel:+61-8-6488-4489 
         Fax:+61-8-6488-7247 
                   E:rebecca.fuller@uwa.edu.au 
 
 
GRAPHICAL ABSTRACT  
 2 
 
ABSTRACT  
Developing targeted validation probes that can interrogate biology is of interest for both chemists 
and biologists. The synthesis of suitable compounds provides a means for avoiding the costly 
labeling of cells with specific antibodies and the bias associated with the interpretation of 
biological validation experiments. The chemotherapeutic agent, tamoxifen has been routinely 
used in the treatment of breast cancer for decades. Once metabolized, the active form of 
tamoxifen (4-hydroxytamoxifen) competes with the binding of estrogens to the estrogen 
receptors (ER). Its selectivity in ER modulation makes it an ideal candidate for the development 
of materials to be used as chemical probes. Here we report the synthesis of a fluorescent 
BODIPY®FL conjugate of tamoxifen linked through an ethylene glycol moiety, and present 
proof-of-principle results in ER positive and ER negative cell lines. Optical microscopy indicates 
that the fluorescent probe binds selectively to tamoxifen sensitive breast cancer cell lines. The 
compound showed no affinity for the tamoxifen resistant breast cancer lines. The specificity of 
the new compound make it a valuable addition to the chemical probe tool kit for estrogen 
receptors. 
KEYWORDS Tamoxifen • Fluorescent probe • fluorescent tamoxifen derivative • Estrogen 
Receptor 
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Estrogens, such as 17b-estradiol, are well-known steroid hormones that play a central role in 
regulating a number of normal cell processes including proliferation and differentiation.1,2 These 
hormones bind to a number of different receptors in cells, including the estrogen receptor (ER). 
The binding of the steroid to this nuclear receptor leads to a conformational change of the ER 
which results in the formation of a docking site for the binding of cofactors needed for 
transcription.3 Overexpression in the ER is associated with 75-80% of breast cancers.4,5 Hence ER 
ligands have found widespread clinical use in modern medicine. Tamoxifen (Figure 1) is one 
such example that is widely administered for the treatment of breast cancer. This non-steroidal 
small molecule modulates estrogen receptors (ER).6 By competing for binding with the 17b-
estradiol hormone it prevents the conformational change of the ER, and hence the associated 
transcription no longer occurs.7,8 
 
 
 
 
 
Figure 1 Tamoxifen 
 
Despite the clinical success of Tamoxifen, like other estrogen therapies it has side effects for 
non-target tissues, including hot flushes as well as more serious conditions such as endometrial 
cancer.9 These adverse side affects are likely the result of the tamoxifen acting through different 
targets. 5,10 It is believed that the endometrial cancer could be due to the formation of DNA 
adducts.11 However, the exact mechanisms are still unknown, which in part is due to a lack of 
experimental tools to identify targets. Fluorescently tagging bioactive molecules through the 
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conjugation of a fluorophore to a bioactive compound is one solution to this problem. These 
compounds are known to provide an invaluable tool for cellular-based microscopy.12 
 
The development of new chemical probes based on Tamoxifen is one strategy for further 
understanding the mechanisms of estrogen signaling and the specific physiological responses 
associated. Tamoxifen and the active metabolite 4-hydroxytamoxifen (OHT) represent ideal 
candidates to base new ER targeted compounds on. Despite the simplicity of this approach, 
relatively few examples are found for these compounds.13-15 Although these probes would be 
useful in ER detection and imaging,14 they are unlikely to be useful for investigating the much 
debated membrane associated ERs.16,17 This is because these probes either have no specificity for 
breast cancer cell lines,13 or do not involve the addition of a linker molecule, 14,15 known to be a 
useful strategy for developing conjugates that target membrane receptors.18 The loss of specificity 
and complex uptake pattern seen by others,13 was attributed to several factors including the 
hydrophobic nature of the linker and/or fluorophore tags. 19 In this work we have attempted to 
simplify the cellular localisation while maintaining selectivity of the tamoxifen probe through the 
introduction of a more hydrophilic linker shown to maintain ER selectivity.20 We herein report 
the synthesis of a fluorescent analogue of tamoxifen, based on conjugating the BODIPY®FL 
fluorophore through an ethylene glycol moiety. We find that our new probe appears to be both 
cell permeable and selective.  
 
Tamoxifen represents an ideal small molecule to base ER probes on. However, to date only three 
examples of fluorescent Tamoxifen probes have been developed. 13-15 Two of these were based on 
the direct attachment of dyes to tamoxifen or its metabolite. 14 Although these probes have good 
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binding affinity and selectivity, they would not be useful for interpreting the contentious 
membrane receptor problem.  To date the only tamoxifen probes developed for membrane 
associated ER studies have had poor affinity and loss of specificity compared to the parent 
compound.13 The design of our conjugate has been in response to this.  
 
Since the triphenylethylene core is the motif required to bind to the ER, the attachment of the dye 
has been made through the basic alkylaminoethoxy side chain, which is accepted to protrude out 
of the receptor binding pocket.21 A short ethylene glycol linker was thought to be the best 
approach for the conjugation of the dye to the tamoxifen. Bulky hydrophobic side chains have 
been proposed for reduced specificity and affinity in conjugated fluorescent tamoxifen.13 It has 
been predicted that the highest binding affinities are observed for bivalent 4-hydroxytamoxifen 
compounds with very short ethylene glycol linkers. 22,23 Cell specificity was achieved for an 
optical probe based on a nanoparticle conjugated to tamoxifen through a short ethylene glycol.20  
 
Although the metabolite of the drug, OHT has 30-100 times more affinity for the ER,24 we have 
chosen to tether the fluorophore directly to tamoxifen. In addition to being commercially 
available, sufficient binding has been found for probes based on tamoxifen rather than the 
metabolite.15 A large number of commercial dyes exist, we have chosen to use the BODIPY®FL 
fluorophore as it has been well characterized as a cell permeable fluorophore. Although not cell 
specific the BODIPY®FL conjugated OHT has displayed unusual localisation in the cytoplasm 
making it an ideal choice for our dye. 19,13 
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The synthesis of tamoxifen conjugated with BODIPY®FL is outlined in Scheme 1. We have 
used a traditional conjugation approach to develop the probe compound based on tamoxifen.25 
Briefly, the tertiary amine of commercially available tamoxifen was demethylated using α-
chloroethyl chloroformate to produce the quaternary ammonium salt 1.26 Subsequent nucleophilic 
substitution between monotosylated polyethylene glycol 2 27 and the amine hydrochloride 1 
afforded tertiary amine 3. The terminal hydroxyl group of 3 was then tosylated to give compound 
4, and then substituted with thioacetate to give 5. Thioacetate 5 was then hydrolysed to give the 
thiol 6 and subsequently conjugated with the the thiol active maleimide BODIPY®FL 
fluorophore NHS ester to give the BODIPY®FL conjugated tamoxifen 7. 
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Scheme 1 Synthesis of BODIPY®FL conjugate of tamoxifen 7. 
 
 
 
The cellular localisation of 7 in ER-positive MCF7 and ER-negative MDA231 breast cell lines 
was visualised by fluorescent confocal microscopy.28 Following incubation of the cells with the 
conjugate, uptake studies found that 7 was internalised in the ER-positive but not ER-negative 
cells (Figure 2). The specific uptake pattern suggests a receptor-mediated mechanism of uptake. 
No difference in degree of uptake or localisation is found with an increase in concentration of 7. 
We did not find any localisation of the BODIPY®FL conjugate in the cytoplasm. 
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Figure 2. Confocal images of MCF7 (a-c) and MDA231 (d-f) cells following incubation with 
low (b,e) and high (c,f) concentrations of (7) compared to untreated control cells (a) and (d). 
 
Tamoxifen has been administered as a chemotherapeutic agent for the treatment of breast cancer 
for over three decades. The active form of the drug competes with estrogen in the binding of ER 
sites. The selectivity of this small compound makes it an ideal candidate to develop fluorescent-
based detection tools. Despite the potential of this small compound there are very few examples 
of fluorescent-based analogues found in the literature, and those that have been reported have  
associated drawbacks. Hence, this project has involved the development of a fluorescently 
labeled analogue of tamoxifen by conjugating a fluorescent BODIPY®FL group via an ethylene 
glycol linker unit. Preliminary cell testing shows that the molecule has maintained its cell 
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specificity in breast lines and lays the foundation for further characterization with other estrogen 
receptor positive cell lines. 
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365 nm UV lamp or staining with phosphomolybdic acid stain solution. Column chromatography 
was performed using silica gel 60 (0.063-0.200 nm) as supplied by Merck, unless otherwise 
stated. HPLC was conducted using an Agilent 1200 with a photodiode array detector (PDA). 
Separation was achieved using a 250 × 10 mm i.d., 5 µm, Apollo C18 reversed phase column 
(Grace-Division) with a 33 mm × 7 mm guard column of the same material. 
 
1H and 13C NMR spectra were acquired in the specified deuterated solvent using either a Bruker 
AV600 (600.13 MHz for 1H and 150.9 MHz for 13C), a Bruker AV500 (500.13 MHz for 1H and 
125.8 MHz for 13C), or a Varian Gemini-400 (399.85 MHz for 1H and 100.5 MHz for 13C) 
spectrometer at 25°C. Chemical shifts are reported in parts per million downfield from 
tetramethylsilane using the residual solvent resonance as internal standard.[20] Data are reported as 
follows: chemical shift, multiplicity (app = apparent, s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad, sept = septet), coupling constant, integration, and assignment.  
High resolution mass spectra (HRMS) were acquired on a Waters liquid chromatograph premier 
(LCT) mass spectrometer using electrospray ionisation (ESI). 
 
Synthesis of N-Desmethyl Tamoxifen (1): Tamoxifen (2.12 g, 5.71 mmol) was dissolved in 
anhydrous CH2Cl2 (60 mL) and the mixture was cooled to 0°C in an ice bath, under an 
atmosphere of argon gas. To this cooled mixture was added 1-chloroethyl chloroformate (0.68 
mL, 0.90 g, 6.30 mmol) in one portion. After 15 min stirring at 0°C, the resulting mixture was 
heated at reflux for 22 hr. After this time, the solvent was removed under reduced pressure to 
obtain a yellow oil. The crude mixture was then dissolved in methanol, refluxed for a further 3 
hours, and then concentrated under reduced pressure. The resulting crude material was subjected 
to silica gel flash column chromatography (CH2Cl2 → 10:90 MeOH/CH2Cl2) to give compound 1 
as a colourless solid (2.05 g, 91% yield, Rf = 0.46 in 1:10 MeOH/CH2Cl2). 1H NMR (399.8 MHz, 
d6-DMSO): δ = 7.38-7.30 (m, 2H, 2 × ArH), 7.26-7.05 (m, 8H, 8 × ArH), 6.76-6.69 (m, 2H, 2 × 
ArH), 6.66-6.58 (m, 2H, 2 × ArH), 4.06 (t, J = 5.2 Hz, 2H), 3.16 (t, J = 5.2 Hz, 2H), 2.32 (q, J = 
7.2 Hz, 2H, CH2CH3), 0.80 (t, J = 7.2 Hz, 3H, CH2CH3); 13C NMR (125.77 MHz, CD3OD): δ = 
157.3, 144.9, 143.6, 143.0, 139.7, 137.9, 133.0 (ArCH), 130.8, 130.4 (ArCH), 129.2 (ArCH), 
128.9 (ArCH), 127.7 (ArCH), 127.2 (ArCH), 114.6 (ArCH), 64.2 (CH2), 49.5 (CH2), 33.8 (CH3), 
29.9 (CH2), 13.8 (CH3); HRMS (ESI): calc. Chemical Formula: C25H28NO [M+H - Cl]+ 358.2171, 
found 358.2162. 
 
Synthesis of 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate  (2): 
Tetraethylene glycol (2 mL, 2.25 g, 11.58 mmol) was dissolved in anhydrous CH2Cl2 (25 mL) 
and the mixture was cooled to 0°C in an ice bath, under an atmosphere of argon gas. To this 
cooled mixture was added freshly prepared Ag2O (4.03 g, 17.39 mmol), KI (0.77 g, 4.64 mmol), 
and TsCl (2.21 g, 11.59). The resulting mixture was left to stir at 0°C for 30 min. After this time, 
the Ag2O was filtered off through a pad of celite eluted with 1:12 MeOH/CH2Cl2. The filtrate was 
then concentrated under reduced pressure. The resulting crude material was subjected to silica 
gel column chromatography (CH2Cl2 → 1:4 acetone/CH2Cl2) to give compound 2 as a colourless 
oil (1.78 g, 44% yield, Rf = 0.58 in 1:8 acetone/CH2Cl2). 1H NMR (399.85 MHz, CDCl3): δ = 7.78 
(app d, J = 8.4 Hz, 2H, 2 × ArH), 7.34 (app d, J = 8.4 Hz, 2H, 2 × ArH), 4.16-4.13 (m, 2H, 
CH2OTs), 3.70-3.56 (m, 14H, 7 × OCH2), 2.93 (s, 1H, OH), 2.43 (s, 3H, CH3); 13C NMR (100.54 
MHz, CDCl3): δ = 144.8 (ArC), 132.8 (ArC), 129.8 (ArCH), 127.8 (ArCH), 72.4 (OCH2), 70.6 
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(OCH2), 70.5 (OCH2), 70.3 (OCH2), 70.2 (OCH2), 69.2 (OCH2), 68.5(OCH2), 61.5 (OCH2), 21.5 
(CH3); HRMS (ESI): calc. C15H25O7S [M + H]+ 349.1321, found 349.1323.  
 
Synthesis of (E)-1-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-3-methyl-6,9,12-trioxa-3-
azatetradecan-14-ol (3): N-Desmethyl Tamoxifen (2.05 g, 5.20 mmol) and glycol 2 (2.72 g, 
7.80 mmol) were dissolved in anhydrous DMF (60 mL), under an atmosphere of argon gas. To 
this stirring mixture was added K2CO3 (7.19 g, 5.21 mmol) in one portion. The resulting mixture 
was left to stir at 85°C for 24 hours. After this time, DMF was evaporated under reduced 
pressure and the crude mixture was diluted by the addition of ethyl acetate. The excess K2CO3 
was filtered off through a pad of celite eluted with 1:12 MeOH/CH2Cl2 and the filtrate was then 
concentrated under reduced pressure. The resulting crude material was purified via silica gel 
flash column chromatography (30:70 acetone/ CH2Cl2 → 5:95 MeOH/CH2Cl2 → 20:80 
MeOH/CH2Cl2) to give compound 3 as an oil (1.54 mg, 55% yield, Rf = 0.25 in 1:12 
MeOH/CH2Cl2). 1H NMR (500.13 MHz, CD3OD): δ = 7.35-7.31 (m, 2H, 2 × ArH), 7.27-7.21 (m, 
3H, 3 × ArH), 7.18-7.09 (m, 5H, 5 × ArH), 6.75 (app d, J = 8.9 Hz, 2H, 2 × ArH), 6.53 (app d, J 
= 8.9 Hz, 2H, 2 × ArH), 3.95 (t, J = 5.9 Hz, 2H, OCH2), 3.70-3.55 (m, 14H), 3.40 (s, 1H, OH), 
2.79 (t, J = 5.9 Hz, 2H), 2.67 (t, J = 5.9 Hz, 2H), 2.44 (q, J = 7.4 Hz, 2H, CH2CH3), 2.34 (s, 3H, 
NCH3), 0.93 (t, J = 7.4 Hz, 3H, CH2CH3); 13C NMR (125.77 MHz, CD3OD): δ = 156.8, 143.9, 
142.5, 141.4, 138.3, 131.9 (ArCH), 129.8 (ArCH), 129.5 (ArCH), 128.2 (ArCH), 127.9 (ArCH), 
126.6 (ArCH), 126.1 (ArCH), 113.5 (ArCH), 73.0, 72.7 (CH2), 70.7 (CH2), 70.6 (CH2), 70.4, 69.3 
(CH2), 65.7 (CH2), 61.8 (CH2), 61.7 (CH2), 57.1 (CH2), 56.6 (CH2), 43.4 (CH3), 29.1 (CH2), 13.7 
(CH3); HRMS (ESI): calc. C33H44NO5 [M + H]+ 534.3219, found 534.3233. IR (neat): ʋ = 3415 
(OH), 2870 (-O-CH2), 1605 (-C=C-), 1573, 1507, 1461, 1443, 1349 cm-1. 
 
Synthesis of (E)-1-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-3-methyl-6,9,12-trioxa-3-
azatetradecan-14-yl 4-methylbenzenesulfonate (4): Compound 3 (570 mg, 1.07 mmol) was 
dissolved in anhydrous CH2Cl2 (15 mL) and the mixture was cooled to 0°C in an ice bath, under 
an atmosphere of argon gas. To this cooled mixture was added freshly prepared Ag2O (588 mg, 
2.54 mmol), KI (294 mg, 1.77 mmol), and TsCl (305 mg, 1.60 mmol). The resulting mixture was 
left to stir at 0°C for 30 minutes, then at reflux for 18 hours. After this time, the Ag2O was 
filtered off through a pad of celite eluted with 1:12 MeOH/CH2Cl2. The filtrate was then 
concentrated under reduced pressure. The resulting crude material was subjected to silica gel 
column chromatography (40:60 acetone/ CH2Cl2 → 5:95 MeOH/CH2Cl2 → 20:80 MeOH/CH2Cl2) 
to give compound 4 as a colourless oil (551 mg, 75% yield, Rf = 0.55 in 1:10 MeOH/CH2Cl2). 1H 
NMR (399.85 MHz, CD3OD): δ = 7.76 (app d, J = 8.9 Hz, 2H, 2 × ArH), 7.40-7.29 (m, 4H, 4 × 
ArH), 7.27-7.18 (m, 3H, 3 × ArH), 7.14-7.03 (m, 5H, 5 × ArH), 6.76 (app d, J = 8.9 Hz, 2H, 2 × 
ArH), 6.54 (app d, J = 8.9 Hz, 2H, 2 × ArH), 4.10-4.06 (m, 2H, OCH2), 3.93 (t, J = 5.6 Hz, 2H), 
3.61-3.42 (m, 12H), 2.82 (t, J = 5.6 Hz, 2H), 2.69 (t, J = 5.6 Hz, 2H), 2.43 (q, J = 7.4 Hz, 2H, 
CH2CH3), 2.40 (s, 3H, CH3), 2.34 (s, 3H, NCH3), 0.89 (t, J = 7.4 Hz, 3H, CH2CH3); 13C NMR 
(100.54 MHz, CD3OD): δ = 158.0, 146.4, 145.0, 143.6, 142.6, 139.8, 136.9, 134.4, 132.9 
(ArCH), 131.0 (ArCH), 130.8 (ArCH), 130.4 (ArCH), 129.2 (ArCH), 129.0 (ArCH), 128.9 
(ArCH), 127.7 (ArCH), 127.2 (ArCH), 114.5 (ArCH), 71.5 (CH2), 71.4 (CH2), 71.3 (CH2), 70.9 
(CH2), 69.6 (CH2), 69.5 (CH2), 66.3 (CH2), 57.8 (CH2), 57.2 (CH2), 43.5 (CH3), 29.9 (CH2), 21.7 
(CH3), 13.9 (CH3),; HRMS (ESI): calc. C40H50NO7S [M + H]+ 688.3308, found 688.3320.  
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Synthesis of (E)-S-(1-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-3-methyl-6,9,12-trioxa-3-
azatetradecan-14-yl) ethanethioate (5): Compound 4 (98 mg, 0.14 mmol) was dissolved in 
anhydrous THF (2 mL), under an atmosphere of argon gas. To this mixture was added KSAc (81 
mg, 0.71 mmol). The resulting mixture was heated at reflux for 16 hours. After this time, the 
residue was diluted with EtOAc and decoloursing charcoal was added.  The decoloursing 
charcoal was filtered off through a pad of celite eluted with 1:12 MeOH/CH2Cl2 and the filtrate 
was then concentrated under reduced pressure. The resulting crude material was purified via 
silica gel flash column chromatography (40:60 acetone/ CH2Cl2 → 5:95 MeOH/CH2Cl2) to give 
thioacetate 5 as an oil (38 mg, 46% yield, Rf = 0.71 in 1:12 MeOH/CH2Cl2). 1H NMR (399.85 
MHz, CD3OD): δ = 7.36-7.28 (m, 2H, 2 × ArH), 7.27-7.19 (m, 3H, 3 × ArH), 7.19-7.04 (m, 5H, 
5 × ArH), 6.75 (app d, J = 8.9 Hz, 2H, 2 × ArH), 6.59 (app d, J = 8.9 Hz, 2H, 2 × ArH), 3.93 (t, J 
= 5.9 Hz, 2H), 3.69-3.46 (m, 12H), 3.06 (t, J = 6.5 Hz, 2H), 2.80 (t, J = 5.9 Hz, 2H), 2.68 (t, J = 
5.9 Hz, 2H), 2.44 (q, J = 7.4 Hz, 2H), 2.35 (s, 3H, CH3), 2.30 (s, 3H, CH3), 0.91 (t, J= 7.4 Hz, 3H, 
CH3); 13C NMR (100.54 MHz, CD3OD): δ = 195.4, 156.7, 143.8, 142.4, 141.3, 138.3, 135.5, 
131.8 (ArCH), 129.7 (ArCH), 129.5 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 126.5 (ArCH), 126.0 
(ArCH), 113.4 (ArCH), 70.6 (CH2), 70.5 (CH2), 70.4 (CH2), 70.3 (CH2), 69.8 (CH2), 69.2 (CH2), 
65.7 (CH2), 57.1 (CH2), 56.5 (CH2), 43.4 (CH3), 30.6 (CH3), 29.0 (CH2), 28.9 (CH2), 13.6 (CH3); 
HRMS (ESI): calc. C35H46NO5S [M + H]+ 592.3097, found 592.3085.  
 
Synthesis of (E)-1-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-3-methyl-6,9,12-trioxa-3-
azatetradecane-14-thiol (6): Thioacetate 5 (50 mg, 0.084 mmol) was dissolved in degassed 
EtOH (400 µL), under an atmosphere of argon gas. To this mixture was added a solution of 
NaOH in degassed H2O (200 µL, 7 M).  The resulting mixture was heated at reflux for 2 hr. After 
this time, the reaction mixture was diluted with dichloromethane (4 mL). The layers were 
separated and the organic layer was washed with brine (1 mL). The organic layer was then 
filtered through a small plug of silica eluted with 5:95 MeOH/CH2Cl2 and concentrated to give 
thiol 6 as an oil (33 mg, 71% yield, 0.72 in 1:12 MeOH/CH2Cl2). 1H NMR (600.13 MHz, CDCl3): 
δ = 7.36-7.32 (m, 2H, 2 × ArH), 7.28-7.22 (m, 3H, 3 × ArH), 7.19-7.15 (m, 2H, 2 × ArH), 7.13-
7.10 (m, 3H, 3 × ArH), 6.76 (app d, J = 8.9 Hz, 2H, 2 × ArH), 6.53 (app d, J = 8.9 Hz, 2H, 2 × 
ArH), 3.97-3.93 (m, 2H, OCH2), 3.72-3.56 (m, 12H), 2.86 (t, J = 6.72 Hz, 2H), 2.83-2.78 (m, 
2H), 2.72-2.66 (m, 2H), 2.45 (q, J = 7.42 Hz, 2H, CH2CH3), 2.36 (s, 3H, NCH3), 0.92 (T, J = 7.42 
Hz, 3H, CH2CH3); 13C NMR (100.54 MHz, CDCl3): δ = 156.8, 143.9, 142.5, 141.4, 138.3, 135.6, 
131.9 (ArCH), 129.8 (ArCH), 129.5 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 126.6 (ArCH), 126.0 
(ArCH), 113.4 (ArCH), 77.4, 70.7 (CH2), 70.6 (CH2), 70.5 (CH2), 70.4 (CH2), 69.5 (CH2), 65.9 
(CH2), 57.2 (CH2), 56.7 (CH2), 43.5 (CH3), 30.1 (CH2), 29.1 (CH2), 13.7 (CH3); HRMS (ESI): calc. 
C33H44NO4S [M + H]+ 550.2991, found 550.3018.  
 
Conjugation of (E)-1-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-3-methyl-6,9,12-trioxa-3-
azatetradecane-14-thiol with BIODPY fluorophore (7): Commercially available BODIPY® 
FL N-(2-aminoethyl)maleimide (Life Technology, 5 mg) was dissolved in dry DMSO (2 × 0.25 
mL) and transferred to a flask containing thiol 6 (10 mg). The resulting mixture was left to stir at 
room temperature under an atmosphere of argon gas, overnight, in the dark. After this time, the 
reaction mixture was diluted with methanol, separated into two batches and then freeze-dried 
using a lyophilizer to give a crude orange solid. Each batch of dry lyophised sample was then 
dissolved in methanol (1 mL) and separated by HPLC. The column was eluted at 4 mL/min with 
an isocratic mobile phase consisting of 65% acetonitrile: 35% of 0.1% TFA/water over 40 min. 
 14 
UV absorbance was measured at wavelengths of 280, 488, and 508 nm. Fractions were collected 
every minute for 40 min. A sample of 7 eluted between 15 and 20 min. The fractions containing 
the appropriate product were then concentrated under reduced pressure to remove acetonitrile 
and then freeze-dried using a lyophilizer to give 7 as an orange solid (3 mg).1H NMR (600.13 
MHz, CD3OD): δ = 7.41 (s, 1H, C=CH), 7.37-7.33 (m, 2H, 2 × ArH), 7.29-7.25 (m, 1H, 1 × 
ArH), 7.22-7.20 (m, 2H, 2 × ArH), 7.17-7.07 (m, 5H, 5 × ArH), 6.99 (app d, J = 4.14 Hz, 1H, 
C=CH), 6.83 (app d, J = 8.9 Hz, 2H, 2 × ArH), 6.65 (app d, J =8.9 Hz, 2H, 2 × ArH), 6.30 (app 
d, J = 4.14 Hz, 1H, C=CH), 6.20 (s, 1H, C=CH), 4.24-4.22 (m, 2H), 3.84-3.80 (m, 2H), 3.70-
3.55 (m, 12H), 3.05-2.99 (m, 2H), 2.97 (s, 3H, CH3), 2.86-2.80 (m, 2H), 2.55-2.52 (m, 2H), 2.49 
(s, 3H, CH3), 2.44 (q, J = 7.55 Hz, 2H, CH2CH3), 2.27 (s, 3H, NCH3), 0.90 (s, 3H, CH2CH3); 
HRMS (ESI): calc. C47H55BF2N3O5S [M+H]+ 822.3924, found 822.3921.  
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2081-2082. 
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28. Cell Culture and bioconjugate incubation: The ER positive MCF7 and ER negative 
MDA231 breast cancer cells were cultured in RPMI media plus 10% fetal bovine serum (Life 
Technologies) and grown at 37°C in a humidifying incubator.  Cells were sub-cultured onto glass 
coverslips in sterile six-well plates at a concentration of 4 x 105 cells/mL for labeling 
experiments. Sub-confluent cultures were incubated for one hour in bodipy-labelled tamoxifen 
(7) diluted in culture media to 10 µg/mL (low conc. TAM) or 100 µg/mL (high conc. TAM), 
then rinsed and replaced into normal growth media immediately prior to imaging. Live stained 
cells were mounted under buffered saline and visualized on a Nikon A1Si fluorescent confocal 
microscope.  Sequential fields were captured in the z-plane to confirm internal cellular 
localization. 
 
 
 
